John Inge Johnsen

This study identifies circadian gene network disruption in high-risk neuroblastoma across multiple biological contexts, showing it is a network-level alteration rather than a single-gene effect.

This study identifies the FBXL12-FANCD2 pathway as a vulnerability in MYCN-driven neuroblastoma, showing its role in replication stress tolerance and potential as a therapeutic target.

This study shows ALK R1275Q mutation sustains an immature SCP-like cell state during sympathoadrenal commitment, increasing susceptibility to MYCN-driven neuroblastoma initiation.

This study shows METTL3 and MYCN cooperate to maintain undifferentiated neural crest cells in neuroblastoma, and METTL3 inhibition promotes differentiation and chemosensitivity.

This paper develops a zebrafish model for medulloblastoma drug testing, showing that neural stem cell culture conditions enhance tumor cell homing and aggressiveness, enabling high-throughput screening.